Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways by Mohammadreza Zamanian et al.
Zamanian et al. Cancer Cell Int  (2016) 16:56 
DOI 10.1186/s12935-016-0329-y
PRIMARY RESEARCH
Calreticulin mediates an invasive breast 
cancer phenotype through the transcriptional 
dysregulation of p53 and MAPK pathways
Mohammadreza Zamanian1,2, Lama Abdel Qader Hamadneh3, Abhi Veerakumarasivam2,4, 
Sabariah Abdul Rahman5, Shamarina Shohaimi6 and Rozita Rosli2,7*
Abstract 
Background: The introduction of effective novel biomarkers of invasion and metastasis is integral for the advance-
ment of breast cancer management. The present study focused on the identification and evaluation of calreticulin 
(CRT) as a potential biomarker for breast cancer invasion.
Methods: Two-dimensional gel protein electrophoresis and MALDI-TOF were utilized in the analysis of fresh-frozen 
invasive intra-ductal carcinoma specimens. Calreticulin-associated expression was analyzed using immunohistochem-
istry of FFPE non-malignant/malignant breast specimens. A CRT-knockdown model of MCF7 cell line was developed 
using siRNA and the CRT genotype/phenotype correlations based on migration and trans-well invasion assays were 
determined. Finally, microarray-based global gene expression profiling was conducted to elucidate the possible cal-
reticulin pro-invasive regulatory pathways.
Results: Two-dimensional gel protein electrophoresis and MALDI-TOF analysis showed upregulation of calreticulin 
expression in tumor tissues as compared to the normal adjacent tissues. Meta-analysis of the immunohistochemical 
results confirmed significantly higher expression of calreticulin (p < 0.05) in the stromal compartments of malignant 
tissues as compared to non-malignant tissues. Migration and transwell invasion assays showed significant loss in the 
migratory and invasive potential of CRT-knockdown cells (p < 0.05). Global gene expression profiling successfully 
identified various putative gene networks such as p53 and MAPK pathways that are involved in calreticulin breast 
cancer signaling.
Conclusion: Besides confirming calreticulin overexpression in invasive breast cancer tissues, this study reveals 
a calreticulin-dependent pro-invasive potential and suggests possible contributing pathways. Defining the mechanis-
tic role of invasion and characterizing the possible calreticulin-dependent molecular targets will be the focus of future 
work.
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Background
Breast cancer is a major health problem for women as 
it is diagnosed at least a million times every year world-
wide [1]. In the United States, it is the second leading 
cause of cancer deaths and the most common cancer 
among women [2]. In Asian countries, the peak age for 
the disease is between 40 and 50 with an increasing trend 
in incidence and associated mortality  [3]. The  ability 
to  accurately predict the presence of distant metastasis; 
the direct consequence of  the invasive ability of cancer 
cells  significantly aids in the determination of effective 
patient management strategies [4].
Calreticulin (CRT) is an important endoplasmic retic-
ulum (ER) protein with critical functions inside and 
outside the ER [5]. Protein chaperoning and calcium 
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homeostasis are the two key functions of calreticulin 
inside the lumen of the ER [6]. Outside the ER, calreticu-
lin is involved in cell adhesion [7], modification of gene 
expression [8], and immune response [9]. Calreticulin is 
also reported to be correlated with cellular proliferation 
and metaplastic events [8]. In addition, calreticulin has 
also been linked to malignant states [10], and as a major 
calcium homeostasis contributor, it plays a role in cancer 
invasion and metastasis [11]. Recent studies have focused 
on revealing an association between the presence of 
calreticulin and the initiation  or  progression of vari-
ous malignant transformations [12]. In brief, the tumor-
promoting effects of calreticulin  or its overexpression 
has been reported in ductal carcinoma of the breast [13], 
bladder cancer [14], and prostatic adenocarcinoma [15]. 
Furthermore, hepatocellular carcinoma [16], pancreatic 
malignancies [17], esophageal cancer [18], gastric can-
cer [19], colon cancer [20], melanoma [21], and leukemia 
[22] have also been reported to be potentially correlated 
with calreticulin activity.
A higher expression of calreticulin protein in breast 
ductal adenocarcinomas has been previously reported 
[13], which possibly indicates to a correlation between 
the presence of calreticulin and the initiation and/or pro-
gression of cancer. Calreticulin overexpression was also 
found to be associated with a higher risk of developing 
invasion and metastasis in breast cancer patients [23]. In 
addition, calreticulin has been suggested to be a potential 
biomarker for breast cancer prognosis as its expression 
was associated with more advanced tumors [24].
Taken together, calreticulin is believed to be involved 
in the initiation and progression of various cancers. In 
breast cancer, calreticulin expression has been corre-
lated with more advanced disease and a higher chance 
for the development of distant metastasis. As the mecha-
nisms and the pathways through which calreticulin may 
contribute to breast cancer invasion and metastasis have 
not been determined, we first tried to clarify the impor-
tance of calreticulin stromal expression in conferring a 
more invasive phenotype to breast cancer and to subse-
quently propose possible mechanisms or pathways for 
calreticulin pro-invasive effects. The proteomic compo-
nent of the present study revealed calreticulin as differen-
tially expressed in various invasive states of breast cancer. 
Then we focused on evaluating the possible correlations 
between calreticulin  expression and the  conferment of 
an  invasive phenotype  in breast cancer cells as well as 
clarifying the related mechanisms. We aimed to probe 
the patterns of differential expression of calreticulin in a 
range of human breast tissues including non-malignant 
and malignant lesions. Subsequently, we established the 
role of CRT in conferring an invasive phenotype in breast 
cancer cells through siRNA gene knockdown and whole 
genome expression profiling.
Results
Two-dimensional gel electrophoresis protein maps in the 
range of pH 4–7 were obtained in duplicates and protein 
spots that were differentially expressed between tumor 
and adjacent normal epithelial tissues were selected. 
Figure  1a shows a representative gel where the protein 
spots are circled. Spots that were differentially expressed 
across different samples were excised and sent for 
MALDI-TOF analysis. Figure 1b represents the MALDI-
TOF spectrogram for calreticulin tryptic peptides while 
all of the correlated identified spots are also listed in 
Additional file 1: Table S1. The results revealed that cal-
reticulin is overexpressed in the  tumoral regions  of the 
tissue samples (spot 2 in Fig.  1a). Figure  1c represents 
calreticulin expression in different intra ductal carcinoma 
(IDC) samples including the tumoral and normal adja-
cent tissues. By using  qPCR, CRT expression was con-
firmed to be higher in stages III and IV of breast cancer 
as  compared to stage I and II tumors  (Fig.  1d). Results 
from protein profiling revealed differential  calreticulin 
expression patterns between tumoral and normal adja-
cent tissues of breast cancer specimens.
To confirm our protein profiling results and character-
ize the histological pattern of calreticulin expression, we 
applied IHC on a range of breast cancer specimens with 
varying degrees of invasive potential. Our results con-
firmed that in non-malignant tissues, calreticulin expres-
sion was more prominent in the glandular compartment 
as compared to the stroma (Fig.  2a). The expression 
was mostly cytoplasmic while low intense staining of 
the nucleus and cell membrane was also detectable. In 
malignant tissues, calreticulin was expressed in both 
the epithelial and stromal compartments (Fig.  2b). The 
expression was high in almost all malignant epithe-
lial cells while inside the tumor stroma, high expression 
of calreticulin could be observed in spindle shaped cells 
of the stroma. The pattern of expression revealed that the 
higher the invasive state of the tissue, the more calreti-
culin  was expressed. To quantify the differences in cal-
reticulin expression among various malignant states, 
IHC results were scored and the different categories 
(non-malignant/malignant/stage/grade) were compared 
(Fig.  2c). One-way ANOVA followed by post hoc test 
(Duncan option) demonstrated a significantly higher 
expression of calreticulin in the  stromal compartments 
of  malignant tissues as compared to non-malignant tis-
sues; as F(3, 41) = 4.985 and p = 0.005 (Table 1). 
Since IHC confirmed the differential expression of 
calreticulin in breast cancer tissues, we developed an 
in  vitro CRT-knockdown model of breast cancer using 
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siRNA to examine the effects of CRT expression modu-
lation  on the  invasive potential of MCF7 breast cancer 
cells. The level of CRT expression decreased by 87 % fol-
lowing siRNA transfection (Additional file  2: Table S2; 
Fig.  3a), which confirmed the successful knockdown of 
CRT. This was further confirmed by western blot analy-
sis (Fig. 3b). In addition, MTT assay was used to evaluate 
the presence of potential cytotoxic effects of the  siRNA 
and transfection reagent. The mean viability of the CRT-
knockdown cells remained at about 90 % as compared to 
untreated cells (Fig. 3c).
The invasive characteristics of CRT-knockdown cells 
were then investigated using phenotypic assays. The 
migration assay (Additional file  3: Table S3; Figs.  3d, 4) 
revealed a significant decrease in the  migratory poten-
tial of CRT-knockdown cells as compared to the control 
group (p  <  0.05). The  treatment with mitomycin-C did 
not alter this effect, suggesting that the inhibitory effect 
of calreticulin on migration is not proliferation-depend-
ent (p < 0.05).
The mean number of invaded CRT-knockdown cells 
in a matrigel invasion assay (Additional file  4: Table 
S4; Fig.  5) was compared against  the controls (Fig.  3e). 
There was a significant decrease (p  <  0.05) in the num-
ber of invaded CRT-knockdown cells as compared to the 
control cells.
We then tried to identify possible CRT-associated sign-
aling pathways using gene expression microarrays. A 
total of 1579 genes were significantly upregulated while 
992 genes were downregulated in  the  CRT-knockdown 
cells. The 10 most up/downregulated genes are summa-
rized in Table 2. The validity of the microarray data was 
confirmed using qPCR (Fig. 6). 
To understand the biological significance of the 
global changes in the patterns of gene expression, related 
gene ontologies were analyzed. GeneCards® which is one 
of the options of GeneDecks V3 software was used for 
annotation classification. DAVID (Database for Annota-
tion, Visualization and Integrated Discovery) was also 
used to reveal functional relationships of the  proposed 
Fig. 1 Two-dimensional gel electrophoresis and MALDI-TOF mass spectra analysis reveal calreticulin as over expressed in breast cancer tissues. a 
A representative 2D gel electrophoresis map for the tumor tissue from a stage III sample after running on 17 cm pH 4–7 IPG strips. Spots 1 through 
9 were excised and the protein identification was determined by MALDI-TOF analysis, in which spots 1–5 and spot 9 were over-expressed in the 
tumor tissue, while spots 6–8 were down-regulated. b MALDI-TOF mass spectrum of the tryptic peptides corresponding to calreticulin. c Expression 
of calreticulin in different intra ductal carcinoma (IDC) samples (T tumoral tissue, N normal adjacent tissue). d Graph represents the CRT expression 
fold change across different stages of infiltrating ductal breast carcinoma specimens
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subsets of genes and related ontologies. Some of the most 
important and related ontologies for up/down-regulated 
genes are summarized in Additional file 5: Table S5. The 
genes in each category have been previously reported in 
the literature as responsible for or involved in the specific 
ontologies.
Among the significantly upregulated genes, MIA (mel-
anoma inhibitory activity), KLK13 (kallikrein-related 
peptidase 13), HEPACAM (hepatic and glial cell adhe-
sion molecule), MADD (MAP-kinase activating death 
domain), TP53I11 (tumor protein p53 inducible protein 
11), based on the  importance of their cellular localiza-
tion have been reported as being associated with a more 
invasive cancer phenotype. In addition, LGALS3BP (lec-
tin, galactoside-binding, soluble, 3 binding protein), 
MAP3K5 (mitogen-activated protein kinase kinase kinase 
5), TNFSF10 (tumor necrosis factor (ligand) superfamily, 
member 10) which are mainly involved in various  cel-
lular processes are potentially associated with a higher 
invasive potential. Finally, BTG2 (BTG family, mem-
ber 2), RARRES3 (retinoic acid receptor responder 3), 
SERPINA3 (serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3), SMPD3 (sphin-
gomyelin phosphodiesterase 3, neutral), XAF1 (XIAP 
associated factor 1), SERPINB5 (serpin peptidase inhibi-
tor, clade B (ovalbumin), member 5) and TP53TG5 are 
important cancer-related genes that  were also signifi-
cantly up-regulated in this study.
Among the significant downregulated genes, CCT5 
(chaperonin containing TCP1, subunit 5), DBF4, HDAC4 
(histone deacetylase 4), HDAC4 and TAF3 with important 
cellular localizations were shown to be correlated with 
higher invasive potential. In addition, CALB2 (calbindin 
2) or calretinin, MAPRE2 (microtubule-associated pro-
tein, RP/EB family, member 2), RNASE1 (ribonuclease, 
RNase A family, 1), ESRRG or estrogen related recep-
tor gamma, MAPK8 (mitogen-activated protein kinase 
8) and PCMT1 (protein-L-isoaspartate (D-aspartate) 
Fig. 2 Immunohistochemistry results and the comparison of the expression levels of calreticulin in various invasive states of breast cancer. a 
Immunohistochemical staining of calrecticulin expression in non-malignant lesions of human breast. (I) Negative control. (II) Positive staining in 
the glandular (white arrow) and stromal compartments (black arrow), ×10 magnification. (III) Positive staining in glandular (white arrow) and stromal 
compartments (black arrow), ×40 magnification. b Immunohistochemical staining of calreticulin expression in malignant lesions of human breast. 
(I) Negative control. (II) Positive staining in malignant glandular epithelium (black arrows) and stromal parts (white arrows) of the tumor, ×10 magnifi-
cation. (III) Positive staining in glandular parts of breast tumor. (IV) Breast tumor with invasive pattern, ×10 magnification. (V) Breast tumor with inva-
sive pattern, ×40 magnification. (VI) Calreticulin expression in stromal cells with spindle shapes (arrows). c (I) Differential expression of calreticulin 
in different stages of breast cancer. Calreticulin expression is presented based on the localization in three different tissue compartments: glandular 
structures, stroma and invasive areas. The expression of calreticulin is stratified according to the stage of the tumor (2, 3, 4) and the intensity of 
expression (low, moderate, high). (II) Differential expression of calreticulin in different grades of breast cancer. Calreticulin expression is presented 
based on the localization in three different tissue compartments: glandular structures, stroma and invasive areas. The expression of calreticulin is 
stratified according to the grade of the tumor (1, 2, 3) and the intensity of expression (low, moderate, high)
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O-methyltransferase) which are involved in various  cel-
lular processes have been reported to be associated with 
a  more invasive cancer phenotype. Finally, C11orf17 (A 
kinase interacting protein 1), MAP2K6 (mitogen-activated 
protein kinase kinase 6: MKK6), PARD6A (par-6 parti-
tioning defective 6 homolog alpha), MINA (MYC induced 
nuclear antigen), NUDT6 (fibroblast growth factor 2: 
FGF-2), PSMD10 (proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 10: p28), PSMD10, FABP3 (fatty 
acid binding protein 3), AMPK (AMP-activated protein 
kinase) and PRND (prion protein 2) have been suggested 
to potentially contribute towards the migratory and mor-
phological behavioral changes of tumor cells.
We also probed for any significant changes in the 
expression of other genes related to calreticulin chaper-
oning or calcium homeostasis. Our results showed sig-
nificant overexpression of ERp57, GRP78 and GRP94 in 
CRT-knockdown breast cancer cells. These proteins are 
actively involved in protein chaperoning inside the ER. 
In addition, ERO1A which codes for an oxidizing enzyme 
involved in the regulation of the redox state of various ER 
proteins showed significant upregulation in CRT-knock-
down genes. Finally, ITPR3 which encodes the receptor 
for inositol 1,4,5-trisphosphate was downregulated in 
CRT-knockdown cells. ITPR3 contains a calcium channel 
and is involved in the release of intracellular calcium.
Table 1 Statistical analysis of  immunohistochemistry 
results for calreticulin expression (ANOVA)
One-way ANOVA showed significantly higher calreticulin expression in stromal 
parts of malignant tissues as compared to non-malignant samples (p < 0.05)




10.854 3 3.618 0.777 0.516
 Within groups 139.617 30 4.654




60.128 3 20.043 4.985 0.005
 Within groups 164.85 41 4.021




28.301 2 14.15 3.213 0.053
 Within groups 145.338 33 4.404
 Total 173.639 35
Fig. 3 The knockdown of CRT expression results in the inhibition of the migratory and invasive potential of MCF7 breast cancer cells. a Relative CRT 
expression analysis shows that more than 87 % decrease in expression was achieved in CRT-knockdown cells. b Western blot results confirmed the 
down regulation of calreticulin expression in CRT-knockdown MCF7 cells as compared to control groups. Beta actin was used as the house-keeping 
control. c MTT assay showed 90.7 % viability in CRT-siRNA transfected MCF7 cells as compared to the untreated group. d Migration assay results 
revealed a significant association between CRT expression and the migratory potential of MCF7 cells. The effect on migration was not proliferation-
dependent. e Statistical analysis of the invasion assay results showed a significant decrease in the number of invading cells following CRT-knock-
down of MCF7 cells
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Fig. 4 Migration assay: comparing the speed in gap closure in a monolayer of cells. The images were captured at 0, 10 and 20 h post scratching. 
The CRT-siRNA knockdown cells displayed an obvious decrease in gap closure rate as compared to the control group in the absence and presence 
of mitomycin-C
Fig. 5 Matrigel invasion assay: micrograph of transwell invaded cells. Control and CRT-knockdown MCF7 cells (black arrow) are shown to have 
invaded through the pores (white arrow)
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Discussion
Our results demonstrate that the level of calreticulin 
expression in breast cancer is directly correlated with 
the invasiveness of the malignant lesions;  represented 
by tumor stage/grade. This is in concordance with pre-
vious studies in which calreticulin overexpression was 
described in breast tumor epithelial cells, in which a 
correlation between calreticulin overexpression and 
the  development of post-operative distant metastasis 
were reported [23, 24]. Calreticulin overexpression have 
also been reported in other malignant lesions such as 
esophageal squamous cell carcinoma [18], gastric cancer 
[19], pancreatic tumors [17], and even in melanoma cells 
[21].
The present study also reveals a significant upregula-
tion of calreticulin in the stromal compartment of malig-
nant tissues as  compared to non-malignant tissues. To 
our knowledge, this is the first report that highlights the 
distinct calreticulin expression in the stroma of breast 
cancer. It is known that the growth and progression of 
malignant lesions entail the involvement of tumor stroma 
[25]. The stroma within the cancer microenvironment 
is usually subjected to different changes such as fibro-
blast activation, remodeling of extracellular matrix and 
finally angiogenesis [26]; where they are thought to act as 
a machinery for transforming the stroma into a protec-
tive microenvironment for metastasis [27]. Among the 
multiple inter players of the stroma/malignant cellular 
reaction, cancer-associated fibroblasts are drawing more 
attention as the receivers and creators of pro-tumorigenic 
signals [28]. In the present study, the characterization of 
calreticulin expression in breast cancer tissues shows the 
potential significance of its expression in the stroma.
The in  vitro part of our study demonstrated that 
the migratory and invasive potential of CRT-knockdown 
MCF7 cells declined significantly as  compared to the 
control groups. At the same time, MTT assay confirmed 
that these changes were not due to the alterations in 
the proliferative activity of the cells. These findings are 
in agreement with recent studies that indicate a role for 
calreticulin in conferring a  pro-invasive and metastatic 
phenotype in a range of cancers, including breast adeno-
carcinoma [24, 29], gastric cancer [19], and esophageal 
squamous cell carcinoma [18].
Although the molecular mechanisms for cancer inva-
sion and metastasis are not fully understood [30], differ-
ent classes of proteins are involved or altered throughout 
this process. These proteins include cell adhesion mol-
ecules (CAMs) such as calcium dependent cadherin fam-
ily, integrins and matrix proteases [31]. As calreticulin is 
also mainly involved in calcium homeostasis and protein 
chaperoning [5], several mechanisms can be proposed for 
its role in cancer initiation and progression. Calreticulin 
is able to prevent the anti-metastatic effects of estrogen 
receptor α (ERα) in breast cancer [29], induce cell migra-
tion and wound healing [32], as well as affect apoptosis 
through the  regulation of calcium stores of the cell [11, 
Table 2 The 10 most up/downregulated genes 
upon knockdown of CRT expression
Genes are listed based on their names, systematic names, fold changes in their 
expression (log FC) and the p values. CRT as the most down-regulated gene is 
shown in bold
Gene name Systematic name Log FC p value
IFIT1 NM_001548 2.9 0.00065
IFIT2 NM_001547 2.5 2.10E−05
IFI6 NM_022873 2.3 0.00016
IFIT3 NM_001549 2.3 0.00033
IFI27 NM_005532 2.2 0.0034
DDX58 NM_014314 2 7.20E−06
DDX60 NM_017631 2 5.00E−05
IFI27 NM_005532 2 0.0045
OASL NM_003733 1.9 2.10E−05
SAMD9 NM_017654 1.9 7.30E−05
CALR NM_004343 −2.7 5.20E−15
MNT AF318360 −2.1 2.30E−13
CA306742 CA306742 −1.5 9.30E−12
FAM35A NM_019054 −0.67 4.90E−06
PCNXL3 NM_032223 −0.58 2.00E−07
C13orf37 NM_001071775 −0.57 2.70E−06
TACC2 NM_206862 −0.56 0.00025
ENST00000301038 ENST00000301038 −0.5 5.40E−07
CPOX NM_000097 −0.46 0.00037
TAOK3 NM_016281 −0.46 0.0023
Fig. 6 Validation of microarray results by qPCR. The relative expres-
sion of selected genes are shown. IFI6 and PARP14 were upregulated 
in CRT-knockdown MCF7 cells while MNT and TACC2 were downregu-
lated
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33, 34]. In addition, calreticulin effects on gene expres-
sion and cell adhesion are modulated indirectly through 
Ca2+ which makes it a central connector molecule inside 
a network of signaling pathways that are  located in the 
endoplasmic reticulum [35]. On the cell surface, cal-
reticulin regulates focal adhesion disassembly through 
the  interaction with TSP/hep I complex suggesting it as 
an important component of the TSP signaling pathway 
that  modulates cytoskeleton structure and supports the 
role in cell adhesion [36].
To propose a model of  CRT gene interactions and 
related molecular pathways involved in conferring a 
more invasive breast cancer phenotype, further bioinfor-
matic  analysis was performed. Functional annotation of 
differentially expressed genes in CRT-knockdown cells 
revealed several dysregulated biological processes which 
can be suggested to be involved in calreticulin-associ-
ated  pro-invasive effects. The most important dysregu-
lated processes amongst the top gene ontologies were 
extracellular region, calcium homeostasis, DNA bind-
ing, regulation of transcription, estrogen metabolism 
and pathways, tumor progression, metastasis and can-
cer related processes. As expected, among the genes that 
were significantly up or downregulated, there were com-
ponents of important signaling pathways such p53 and 
MAPK (Table  3) in which their possible interactions 
with calreticulin may contribute towards a more invasive 
breast cancer phenotype. 
In the p53 pathway, active p53 functions as a transcrip-
tion factor that upon sensing DNA damage or stress, will 
trigger a network of genes and their products such as 
TP53I11, TP53TG5 and SERPINB5 (maspin) that ulti-
mately leads to cell cycle arrest, cellular senescence or 
apoptosis [37]. Our gene expression study confirmed 
that all these three p53 targets were significantly modu-
lated following CRT knockdown in MCF7 cells (Fig. 7a). 
TP53I11 is a tumor suppressor gene  that  is involved in 
apoptosis [38]. TP53TG5 is a novel p53 target gene with 
cell cycle localization and growth suppressive effects in 
glioblastoma cells [39]. Finally, SERPINB5 (maspin) is 
a powerful tumor suppressor gene that is regulated by 
p53 at the transcriptional level and inhibits cell motility, 
invasion, angiogenesis and metastasis [40]. SERPINB5 is 
downregulated in breast cancer [41], and has the ability 
to modify the motility of breast cancer cells in  vitro by 
inhibiting Rac1/Cdc42 activity [42]. In addition, SER-
PINB5 can potently inhibit  the development of brain 
metastasis of breast cancer [43].
Our novel finding; significant upregulation (p  <  0.05) 
of the three p53 target genes following CRT-knockdown 
correlates with the inhibition of the migratory and inva-
sive potential of breast cancer cells. Therefore, we pos-
tulate that calreticulin is possibly able to modify the 
inductive effects of activated p53 on its target genes. The 
mechanism behind calreticulin-blocking effect on p53 
target genes is not clear. However, it can be related to the 
changes in Ca2+ homeostasis as p53 has been reported 
to interact with other Ca2+ binding molecules such as 
S100A2 [44].
The activation of MAPK signaling through the  extra-
cellular signal related kinase pathway (ERK1, 2) and or 
stress activated kinase pathway (JNK/p38 MAPK) will 
lead to sequential phosphorylation events (Fig. 7b), acti-
vation of transcription factors and finally gene expression 
regulation [45]. Erk1 and 2 are the most relevant MAPK 
components for breast cancer development [46], while 
the level of activated p38 expression is reported to be 
associated with the presence of lymph node metastasis in 
breast cancer [47].
Our results suggest that CRT down-regulation in MCF7 
cells will result in significant downregulation (p  <  0.05) 
of the expression levels of some of the components of 
MAPK pathway including MAP2K6 and MAPK8. In 
addition, some of the other MAPK components such as 
MEK1 and MEK4 also showed reduction in their level 
of expression. These findings correspond to the  signifi-
cant decrease in the migratory and invasive potential of 
the cells. Therefore, calreticulin can be proposed to act 
as a potential inducer of the MAPK pathway. This can 
be supported by the fact that MAPK pathway activity is 
also modified by other Ca2+ homeostasis proteins such as 
Ras-GRF1, which is a Ca2+/calmodulin-dependent Ras-
guanine-nucleotide-releasing factor [45], SERCA2 [48], 
and CaMKII (calcium/calmodulin-dependent protein 
kinase II gamma) [49].
Conclusion
This study shows that calreticulin expression in breast 
cancer is correlated with the degree of invasiveness; 
especially when stromal expression is considered. 
Table 3 The fold-change in  gene expression of  p53 
and MAPK related genes from the microarray-based whole 
genome expression analysis of  CRT-knockdown of  MCF7 
cells
Pathway Gene name Systematic name Log FC p value
MAPK MAP2K6 NM_002758 −0.37 0.00091
MAPK8 ENST00000374189 −0.16 0.031
MAP2K1 (MKK1) NM_002755 −0.12 0.31
MAP2K4 (MKK4) NM_003010 −0.11 0.18
MAPK1 (ERK2) NM_138957 −0.01 0.96
MAPK14 (p38) NM_001315 −0.08 0.39
p53 SERPINB5 NM_002639 0.18 0.032
TP53I11 NM_001076787 0.25 0.036
TP53TG5 NM_014477 0.21 0.011
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Furthermore, calreticulin confers a more invasive breast 
cancer phenotype. We conclude that calreticulin is able 
to promote breast cancer migration and invasion through 
the transcriptional  modulation of important genes and 
associated pathways such as MAPK and p53 signaling. 
These downstream genes that have an active contribution 
towards the malignant transformation of cancer cells are 
possibly the actual targets of calreticulin-associated pro-
invasive effects and will need to be further evaluated in 
future studies.
Methods
Human breast tissue samples and breast cancer cell line
Fresh frozen breast cancer tissues for this study were 
obtained from Hospital Universiti Kebangsaan Malaysia. 
Ethics approval and patient informed consent including 
consent to participate in the study and consent to publish 
was obtained in written in accordance to the Universiti 
Kebangsaan Malaysia Research and Medical Ethics Com-
mittee (Approval No. FF-166-2004). Fresh frozen sam-
ples of infiltrating ductal carcinoma and adjacent normal 
tissues were collected from 12 patients who underwent 
breast surgery. The samples were snap frozen and stored 
at −80  °C until protein analysis was performed. For-
malin-fixed paraffin-embedded (FFPE) samples were 
obtained from the Pathology Department of Milad Hos-
pital, Tehran, Iran, courtesy of Dr. Saadat Molanaii. These 
included 10 non-malignant and 38 malignant samples. 
Non-malignant samples were mainly from fibrocystic 
changes of the breast while all of the malignant tissues 
were diagnosed as ductal carcinoma. Malignant samples 
were stratified based on the grade as well as the stage 
of the tumors. MCF7 cell line was purchased from the 
American Type Culture Collection (ATCC) and used for 
the in vitro part of this study,
Two‑Dimensional Gel Electrophoresis
For the first dimension, 17 cm pH 4–7 L IPG strips (Bio-
Rad, Hercules, CA, USA) were used. The samples were 
passively rehydrated overnight using a rehydration buffer 
containing 7 M urea (Bio-Rad), 2 M thiourea (GE health-
care, Uppsala, Sweden), 2 % CHAPS (GE Healthcare), 1 % 
IPG buffer (pH 4–7) (GE healthcare), 0.2  % DTT (Bio-
Rad) and bromophenol blue (Bio-Rad). The rehydrated 
Fig. 7 CRT-knockdown correlates with the modulation of p53 and MAPK pathways. a Possible role of calreticulin in the p53 pathway. Activated p53 
suppresses the processes of tumor formation and progression through the activation of SERPINB5, TP53I11 and TP53TG5. Calreticulin possibly blocks 
p53 stimulatory effects of these processes. b Possible contribution of calreticulin in the MAPK pathway. MEKs are activated following the attach-
ment of growth factors and other ligands to the surface receptors. This leads to the activation of sequential phosporylation processes, enhance-
ment of transcriptional activities and finally regulation of gene expression. MAP2K6 and MAPK8 are two significantly modulated MAPKs following 
CRT knockdown (p < 0.05) while MKK1 and MKK4 have also shown some changes in their expression levels. Calreticulin possibly has a stimulatory 
effect on the production of MKKs
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IPG strips were focused using PROTEAN IEF cell (Bio-
Rad). The current was applied in 3 steps; 250  V was 
applied in linear ramp for 20 min, then 10,000 V for 2.5 h 
in linear ramp and finally, the current increased rapidly to 
40,000 V/hr when the isoelectric focusing was achieved. 
The strips were stored at −80 °C until the second dimen-
sion gel electrophoresis was performed. Strips were then 
equilibrated in two steps for 15 min each using an equi-
libration buffer consisting of 0.1  M Tris HCl (Amresco, 
Solon, OH, USA) pH 8.8, 6 M urea (Bio-Rad) 30 % Glyc-
erol (GE Healthcare), 4 % SDS (GE Healthcare), 0.002 % 
Bromophenol Blue (Bio-Rad). In the first step of equili-
bration, 26 mM DDT (Bio-Rad) was added to the buffer, 
while 0.38  M of Iodoacetamide (Bio-Rad) was added to 
the buffer in the next step. The second dimension was 
then performed on 10 % SDS–polyacrylamide gels.
Gel staining and analysis
The gels were stained with silver staining and scanned 
using the GS-800 Calibrated Densitometer (Bio-Rad). 
The PDQuest software 7.3 (Bio-Rad) was used for differ-
ential analysis of the gels. The spots with at least a two-
fold increase were picked manually and stored at 4  °C 
until in-gel digestion was carried out.
Protein identification by MALDI‑TOF MS
The excised spots were destained by first washing with 
a digestion buffer (25 mM ammonium bicarbonate) and 
then with 50 % acetonitrile digestion buffer. These steps 
were repeated three times. Digestion was performed with 
sequencing grade trypsin (Promega, Madison, WI, USA) 
at 37  °C overnight. The resulting tryptic peptides were 
extracted from the gels, then desalted and concentrated 
with C18 ziptip (Millipore, Billerica, MA, USA) before 
spotting for matrix-assisted laser desorption ionization-
time-of-flight (MALDI-TOF) analysis.
Immunohistochemistry
Immunohistochemistry was performed to evaluate his-
tological expression of calreticulin using a  mouse mon-
oclonal [FMC 75] antibody (Abcam, Cambridge, UK) 
through the following protocol: 0.4 µ tissue sections were 
mounted on polysine-coated slides (Menzel, Berlin, Ger-
many). After dewaxation and dehydration, heat induced 
antigen retrieval was done using Tris–EDTA buffer (pH: 
9.0) for 10  min in sub-boiling conditions. This was fol-
lowed by internal peroxidase inhibition with 3  % H2O2 
for 10  min, blocking with 5  % BSA for 2  h, and then 
treatment with a primary antibody (anti-calreticulin) for 
45 min at a concentration of 0.15 µgr/mL. For detection, 
Real™ EnVision™ Detection System (Dako, Glostrup, 
Denmark) was used for 30  min followed by chromogen 
staining using diaminobenzidine (DAB) for 10  min and 
finally counterstained by hematoxylin. All the procedures 
were carried out at room temperature.
Scoring the IHC results
An independent committee blinded to pathologic details 
of the specimens was assigned to score the IHC results. 
Three different histological areas of each malignant tis-
sue including glandular, invasive and stromal parts 
were examined. These scores were calculated based on 
the intensity of the brown staining (1–3 plus) as well as 
the proportion of stained cells in glandular epithelium 
(<50 % = 0, 70–50 % = 1, 90–70 % = 2 and >90 % = 3) as 
well as stroma (<10 % = 1, 10–50 % = 2 and >50 % = 3).
RNA isolation & cDNA synthesis
Total RNA extraction was performed using RNeasy mini 
kit (Qiagen, Valencia, CA, USA) following the manufac-
turer’s protocol. The concentration and quality of RNA 
were examined by measuring the absorbance ratios at 
260 nm  and 280 nm  using the NanoDrop 2000 spec-
trophotometer (Thermoscientific, West Palm Beach, 
FL, USA) and running the samples on 1  % agarose gel, 
respectively. Finally, the RNA samples were reverse tran-
scribed into cDNA using the Revert Aid™ H minus First 
Strand cDNA Synthesis kit (Thermoscientific) according 
to the manufacturer’s instructions.
Real‑time PCR
The expression level for CRT as the gene of interest and beta 
actin as the housekeeping (reference) gene were examined 
using the  SensiMixPlus SYBR kit (Quantace, London, UK) 
and then quantified based on the standard curve method. 
The primers were designed in a manner to amplify only 
the cDNAs compatible to the mRNA sequence but not the 
genomic sequence. The sequences of the primers for CRT 
are as follows: GGCGGCACCACCATGTACCCT (forward) 
and AGGGGCCGGACTCGTCATACT (reverse) while that 
for beta-actin are CTTCAAGGAGCAGTTTCTGG (for-
ward) and GCTTGTCTGCAAACCTTTATC (reverse). The 
protocol for PCR was as follows: initial denaturation at 95 °C 
for 10 min, denaturation at 95 °C for 30 s, annealing at 52 °C 
(59 °C for beta actin) for 30 s, elongation at 72 °C for 45 s, and 
final elongation at 72 °C for 10 min. The reaction was run for 
35 cycles.
Protein isolation
MCF7 cells were cultured until they reached 70–90  % 
confluence and were then lysed with a solution of 40 mM 
Tris (GE Healthcare, WI, USA), 7  M urea (Invitrogen, 
Carlsbad, CA, USA), 2  M thiourea (Invitrogen), 4  % 
CHAPS (Invitrogen), 65 mM Dithiothreitol (Invitrogen), 
1 mM EDTA (Amresco) and 10 μl of Halt Protease Inhib-
itor Cocktail (Thermoscientific).
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Western blot
The isolated proteins were run on 12.5 % polyacrylamide 
resolving gel and then transferred to a PVDF membrane 
and treated with the primary antibody at 4 °C overnight 
either using 1:200 dilution of mouse monoclonal anti-
body against human calreticulin 1G6A7 (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) or 1:10,000 dilution of 
mouse monoclonal [Ac-15] antibody against human beta 
actin (Genetex, Irvine, CA, USA). This was followed by 
an  incubation in 1:2500 dilution of the  secondary anti-
body (ImmunoPure Goat Anti-Mouse IgG, (H + L), Per-
oxidase Conjugated, Thermoscientific). The detection 
was carried out by a chemiluminescence method using 
SuperSignal West Pico Chemiluminescent Substrate 
(Thermoscientific).
siRNA gene knockdown
For CRT knockdown, ON-TARGETplus SMARTpool 
(Thermoscientific) and DharmaFECT 1 as the transfec-
tion reagent were used. Three controls were included 
in the experiment including untreated, negative and 
mock controls. For negative control (NC), ON-TAR-
GETplus SMARTpool was replaced by non-targeting 
pool of siRNA. In mock control (M), ON-TARGETplus 
SMARTpool was replaced by equal amounts of antibi-
otic- and  serum-free media. Finally, ON-TARGETplus 
SMARTpool and DharmaFECT 1 were replaced by anti-
biotic- and serum-free media in the untreated control 
(UT). For mRNA analysis, cells were harvested 36 h post-
transfection  while protein extraction was carried out at 
72 h post-transfection.
MTT assay
MCF7 cells were cultured on 96-well plates in triplicates 
containing CRT-siRNA transfected or related control 
groups. At 24 h post-transfection, 20 μl of 5 mg/ml MTT 
solution was added to each well and incubated for 3.5 h 
at 37 °C and 5 % CO2. The content of each well was then 
replaced with 100 μl of DMSO (dimethyl sulfoxide). The 
plate was covered with an aluminium foil and agitated in 
an orbital shaker at room temperature for 15 min. Finally, 
the absorbance was read at 590 nm with a reference filter 
at 620 nm using an ELISA reader.
Migration assay
Four triplicates of MCF7 cells were grown on 12-well 
plates and incubated at 37 °C and 5 % CO2 until the cul-
tures reached 70  % confluency. Two sets of cells were 
transfected with CRT-siRNA and the cultures were kept 
at 37  °C and 5  % CO2 for another 72  h. Then,  10  μg/ml 
mitomycin C (Merck, Whitehouse Station, NJ, USA) was 
added to one set of each triplicate (both siRNA treated 
and untreated). After 2 h, a longitudinal scratch was made 
on the central line of each well alongside the pre-applied 
marks at the bottom of each plate. Using a microscope 
with an  attached camera (Leica, Wetzlar, Germany), 
images were captured from the specified marked loci of 
the gaps that were produced by the scratch on the mon-
olayer of cells. Image capturing was repeated at certain 
time points including 0, 3, 6, 10, 15, 20, 24, 28, 32 and 36 h 
post-scratching. Finally, the diameter of the gap was meas-
ured in three different loci of each replicate at the specified 
marked areas using the  Nis-Elements imaging software 
version 3.00 SP7. The average readings were calculated and 
the proportion of differences in the gap diameter at 0 and 
20 h were used to compare the migratory potential of the 
different groups.
Invasion assay
At  48  h post-transfection, the media was replaced by 
serum-free DMEM overnight to simulate starving condi-
tions. The following day, cells were harvested and diluted 
at a concentration of 1  ×  105  cells/mL. The lower com-
partment of BD companion plates (BD, Franklin Lakes, 
NJ, USA) were filled with 750 μl of DMEM including 10 % 
FBS. Then, matrigel-coated inserts were placed inside 
the wells and 500 μl of cell suspension (5 × 104 cells) was 
added into each well and incubated at 37 °C and 5 % CO2 
for 24 h. The inserts were then incubated in 100 % metha-
nol for 10 min, washed in PBS twice and stained in hema-
toxylin for 2–5 min. Finally, the filter membranes were cut 
and mounted on slides using DPX (Merck). The total num-
ber of invaded cells in 10 random HPF was counted at 10× 
magnification of a light microscope.
Genome wide expression analysis
A triplicate hybridization of CRT-siRNA transfected 
MCF7 cells versus mock control was prepared and total 
RNA was extracted 36  h post-transfection. Only RNA 
samples with high quality (A260/A280 and A260/230 
were set at  ≥1.8 and  ≥1.5, respectively) were picked 
for further evaluation. Agilent Whole Human Genome 
Microarray 4  ×  44  K G4112F (Agilent, Palo Alto, CA, 
USA) which, consisted of 43,376 oligonucleotides was 
used for expression profiling. The preparation of expres-
sion arrays, hybridization process and scan readings were 
carried out by Oxford Gene Technology (Oxfordshire, 
UK). The microarray data was deposited in NCBI’s Gene 
Expression Omnibus [50] and is accessible through GEO 
Series accession number GSE44371.
Statistical analysis
For the IHC results, one-way ANOVA followed by post 
hoc test (Duncan option) was used. In other experiments, 
independent Student’s t test was used to determine any 
statistical significance of the results.
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